Monash Health

Running trials

• Not yet recruiting

  NTI164 in Autism Spectrum Disorder

  NCT07257939· Phase 3· Source

• Recruiting

  Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy

  NCT07640191· Source

• Recruiting

  A Study of ARC-02 in B-cell NHL

  NCT07691606· Phase 1· Source

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Not yet recruiting

  Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

  NCT07527819· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· Source

• Recruiting

  A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

  NCT07235293· Phase 2· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Source

• Recruiting

  A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

  NCT07186842· Phase 1/2· Source

• Active, not recruiting

  A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

  NCT07036523· Phase 2· Source

• Recruiting

  Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma

  NCT07245368· Phase 1/2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Recruiting

  A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

  NCT07086105· Phase 1· Source

• Recruiting

  Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

  NCT07055542· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· Source

• Active, not recruiting

  ASCEND CSP IDE Study

  NCT06830746· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· Source

• Active, not recruiting

  Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

  NCT05093231· Phase 2· Source

• Active, not recruiting

  Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

  NCT06727565· Phase 2· Source

• Active, not recruiting

  A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  NCT06679985· Phase 2· Source

• Recruiting

  Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Phase 3· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Source

• Active, not recruiting

  A Study of DM001 in Patients With Advanced Solid Tumors

  NCT06475937· Phase 1· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Source

• Recruiting

  Respiratory Sinus Arrhythmia Pacing Post-CABG Surgery in Patients With HFrEF

  NCT06384963· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Source

• Recruiting

  Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  NCT06500273· Phase 2· Source

• Recruiting

  A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

  NCT06372717· Phase 1· Source

• Active, not recruiting

  A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

  NCT06257264· Phase 1· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  NCT06162221· Phase 1/2· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Source

• Recruiting

  A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

  NCT07630545· Phase 1· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

  NCT06073821· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer3 recruiting
• Colorectal cancer3 recruiting
• Lung cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Ovarian cancer3 recruiting
• Acute myeloid leukemia2 recruiting
• Asthma2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Follicular lymphoma2 recruiting
• Gastric and esophageal cancer2 recruiting
• Heart failure2 recruiting
• Kidney cancer2 recruiting
• Melanoma2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• Ulcerative colitis2 recruiting
• Autism1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Psoriasis1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· Phase 1· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Source

• Completed

  A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

  NCT06064929· Phase 1· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Source

• Terminated

  The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

  NCT04876651· Phase 3· Source

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· Phase 1· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Source

• Terminated

  Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

  NCT05555615· Phase 2/3· Source

• Completed

  Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

  NCT05523895· Phase 2/3· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

  NCT05358717· Phase 2· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  Study of WVE-003 in Patients With Huntington's Disease

  NCT05032196· Phase 1/2· Source

• Terminated

  Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04921358· Phase 3· Source

• Completed

  RegoNivo vs Standard of Care Chemotherapy in AGOC

  NCT04879368· Phase 3· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Source

• Completed

  Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

  NCT04282018· Phase 1/2· Source

• Completed

  Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  NCT04215978· Phase 1· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· Source

• Terminated

  A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

  NCT04082936· Phase 1/2· Source

• Completed

  A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

  NCT03497767· Phase 2· Source

• Completed

  Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

  NCT03795298· Source

• Completed

  A Trial of Radiotherapy and Durvalumab in DLBCL and FL

  NCT03610061· Phase 1· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· Source

• Terminated

  WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

  NCT03302494· Phase 3· Source

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· Source

• Completed

  A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

  NCT02923934· Phase 2· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Source

Trial sites

• Monash Health1 trial
• Monash Health98 trials
• Monash Health13 trials
• Monash Health, Kingston Centre1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Coronary artery disease30 works · 2 trials
• Lupus (SLE)28 works · 1 trials
• Osteoporosis26 works · 0 trials
• Systemic sclerosis (scleroderma)13 works · 0 trials
• Hodgkin lymphoma11 works · 2 trials
• Myelodysplastic syndromes8 works · 4 trials